StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 07:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Press+Releases/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html <ul class="bwlistdisc"> <li> Survey underscores the need for more resources, better preparation </li> <li> Ipsen's <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhealthcare-shift.com%2F%3Futm_source%3Dpress_release%26utm_campaign%3D2026_survey&esheet=54538889&newsitemid=20260520335340&lan=en-US&anchor=Healthcare-Shift.com&index=1&md5=dd4bf1a9b0e90f55541c3def64992764" shape="rect">Healthcare-Shift.com</a> offers a conversation guide, transition checklists and other free resources for teens and families </li> </ul> <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced the findings of a major new survey conducted by The Harris Poll showing broad consensus that young people are under-prepared for the move from pediatrics to the adult healthcare system and more resources are needed to support young adults. </p><p> The Healthcare Shift Survey found 71 percent of youth aged 14-26 find the adult healthcare system confusing, http://www.streetinsider.com/Business+Wire/National+Survey+From+Ipsen+Shows+Young+People+Are+Not+Prepared+for+the+Shift+From+Pediatric+to+Adult+Healthcare/26524761.html Wed, 20 May 2026 07:15:00 -0400 A.18335591 A.23786830 IPN IPSEY O.00374663 O.01160336 O.04960887 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Press+Releases/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Globe+Newswire/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Globe+Newswire/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction http://www.streetinsider.com/Globe+Newswire/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html <ul type="disc"><li>Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo</li><li style="margin-top:12pt; margin-bottom:12pt;">At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity </li><li style="margin-top:12pt; margin-bottom:12pt;">Patient satisfaction scores at Week 24 were 82.8% </li><li style="margin-top:12pt; margin-bottom:12pt;">Corabotase is currently being evaluated as an investigational treatment in aesthetic indications</li></ul> <p><b>PARIS, FRANCE, 16 May 2026 </b>– Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant neuroinhibitor, RNITM. Built from engineered functional domains http://www.streetinsider.com/Globe+Newswire/Ipsen+presents+first-in-class+late-breaking+Phase+II+corabotase+data+in+glabellar+lines+showing+sustained+duration+of+effect+reinforced+by+consistently+high+patient+satisfaction/26508684.html Sat, 16 May 2026 08:00:00 -0400 A.09106209 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.29963876